Europe • Frankfurt Stock Exchange • FRA:LLY • US5324571083
LLY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. While LLY has a great profitability rating, there are some minor concerns on its financial health. LLY is valued quite expensive, but it does show an excellent growth. This makes LLY very considerable for growth investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| ROIC | 28.84% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.41% | ||
| PM (TTM) | 30.99% | ||
| GM | 83.03% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | 6.6 | ||
| Altman-Z | 8.25 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.24 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.34 | ||
| Fwd PE | 31.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 152.92 | ||
| EV/EBITDA | 35.94 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
ChartMill assigns a fundamental rating of 6 / 10 to LLY.DE.
ChartMill assigns a valuation rating of 3 / 10 to ELI LILLY & CO (LLY.DE). This can be considered as Overvalued.
ELI LILLY & CO (LLY.DE) has a profitability rating of 9 / 10.
The Price/Earnings (PE) ratio for ELI LILLY & CO (LLY.DE) is 47.34 and the Price/Book (PB) ratio is 41.37.
The Earnings per Share (EPS) of ELI LILLY & CO (LLY.DE) is expected to grow by 84.93% in the next year.